Skip to main content
. 2023 Sep 28;11(19):e15829. doi: 10.14814/phy2.15829

FIGURE 1.

FIGURE 1

Baricitinib and upadacitinib are associated with suppressed NEDD9 levels in ex vivo CD4+ T cells. (a) Representative example of western blot analysis of NEDD9 in ex vivo CD4+ T cells from the peripheral blood of RA patients and healthy controls (HC). (b) NEDD9 expression in CD4+ T cells analyzed by western blot (HC, n = 15; w/o, n = 8; tofa, n = 13; bari, n = 26; upa, n = 11). (c) Heatmap shows differentially expressed genes in ovarian tumor cells from Nedd9−/− and wild‐type mice (GSE106911, obtained from Gene Expression Omnibus database, |FC| > 2 and p < 0.01) (Gabbasov et al., 2018). –ctrl, negative control; +ctrl, positive control; HC, healthy controls; w/o, RA patients without current treatment; tofa, tofacitinib; bari, baricitinib; upa, upadacitinib. Data are presented as mean ± SD. Significance was calculated using one‐way ANOVA and Tukey's multiple comparison test.